Sweet's syndrome associated with multiple myeloma.
ABSTRACT Sweet's syndrome (SS) is an acute febrile neutrophilic dermatosis. It may be paraneoplastic in 10 to 20% of cases. Association with multiple myeloma (MM) is uncommon.
We report on a 73-year-old woman that developed SS 2 months after being diagnosed with IgG MM. Cutaneous lesions improved rapidly after chemotherapy for the MM. No recurrence of SS has taken place during the subsequent 2 years.
Association of SS with MM has been rarely described in the literature. Only 14 cases of SS with MM have been reported. The secretory status of the MM may influence the occurrence of SS. SS seems to be related to IgG MM. Patients with IgG MM may have more risk of developing SS than those with other secretory types.
- SourceAvailable from: haematologica.orgLa Presse Médicale 03/2013; · 0.87 Impact Factor
- International journal of dermatology 04/2013; · 1.18 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Sweet syndrome is a neutrophilic dermatosis with cutaneous tender lesions that can be associated with malignancies, infections, systemic inflammatory disorders, and medications. Although numerous studies have described Sweet syndrome, few studies have systematically investigated Sweet syndrome. We sought to describe characteristics and treatments of patients with Sweet syndrome and evaluate clinical differences depending on the underlying cause. A retrospective study was conducted to identify patients with Sweet syndrome evaluated at Mayo Clinic from 1992 to 2010. Of 77 patients with Sweet syndrome (mean age of onset 57 years), 43 (56%) were male. Eighteen patients (23%) reported a preceding infection. A total of 41 (53%) patients were classified as having classic Sweet syndrome, 27 (35%) patients had malignancy-associated Sweet syndrome, and in 9 (12%) patients drug-induced Sweet syndrome was considered. In all, 21 patients had a hematologic malignancy or myeloproliferative/myelodysplastic disorder, whereas 6 patients had solid tumors. The mean hemoglobin level, in both male and female patients (P < .0443 and P < .0035, respectively), was significantly lower in malignancy-associated versus classic and drug-induced Sweet syndrome. Systemic corticosteroids were the most frequently used treatment (70%). This is a retrospective study and represents patients from a single academic center. Sweet syndrome is a distinctive disorder with certain clinical and histologic characteristics, which usually has a complete response to systemic corticosteroids. It is important to evaluate Sweet syndrome patients who have laboratory evidence of anemia for an underlying malignancy.Journal of the American Academy of Dermatology 07/2013; · 4.91 Impact Factor